With an increase in body mass index, waist circumference, and an increase in blood glucose, the risk of colorectal cancer increases. The aim of the work was to evaluate metabolic predictors of colorectal cancer in patients of the Republic of Khakassia. The case group includes patients with colorectal cancer. The average age of men is 66.5 (62.7-71.4) years, of women - 62.5 (57.2-67.4) years. The «control» group included patients with metabolic syndrome without malignant neoplasms, similar to the «case» group by sex and age: the average age of men - 53.8 (47.3-57.4) years, women - 61.9 (48, 1-61.6) years. The «control» group included patients with metabolic syndrome without malignant neoplasms, similar to the «case» group by sex and age: the average age of men - 53.8 (47.3-57.4) years, women - 61.9 (48, 1-61.6) years. In the case group with colorectal cancer, excess body weight was recorded in 81.3% of patients before the onset of malignant neoplasms, normal and overweight were more common in men, and obesity of the 1st degree - in women. The number of obese and overweight patients increases after the age of 60, regardless of gender. In addition, among patients with colorectal cancer, there is a statistically significant increase in patients with 5-component metabolic syndrome, both among women and among men. By stratifying patients by body mass index, excess body mass was established in all representatives of the «control» group with metabolic syndrome. After 50 years, the number of men with obesity of 1 and 3 degrees increased, and after 60 years - it sharply decreased. The number of women with grade 1 obesity increased sharply by the age of 60, and remained at a later age. The metabolic syndrome among men under the age of 50 is mainly represented by three terms, in the period 50-60 years, the propor- tion of patients with 4 and 5 components increases, and after 60 years, the multicomponent level decreases sharply. Among women, the expansion of components is also associated with an increase in age, however, after 60 years, the number of patients with metabolic syndrome increased sharply.
colorectal cancer, abdominal obesity, excess body weight, metabolic syndrome
1. Dedov I. I., Mel'nichenko G. A., Shestakova M. V. Troshina E. A., Mazurina N. V., Shestakova E. A., Yashkov Yu. I., Neymark A. E., Biryukova E. V., Bondarenko I. Z., Bordan N. S., Dzgoeva F. H., Ershova E. V., Komshilova K. A., Mkrtumyan A. M., Petunina N. A., Romancova T. I., Starostina E. G., Strongin L. G., Suplotova L. A., Fadeev V. V. Nacional'nye klinicheskie rekomendacii po lecheniyu morbidnogo ozhireniya u vzroslyh. 3-iy peresmotr (lechenie morbidnogo ozhireniya u vzroslyh). Ozhirenie i metabolizm. 2018;15(1):53-70. doi:https://doi.org/10.14341/OMET2018153-70
2. Hoffman E.L.,Von Wald T, Hansen K. The metabolic syndrome. S. D. Med. 2015; Spec No: 24-28.
3. Hdggstrcm C., Stocks T., Rapp K. Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). Int. J. Cancer. 2011. 128(8):1890-8. doihttps://doi.org/10.1002/ijc.25521.
4. Nikitin Yu. P., Openko T. G., Simonova G. I. Metabolicheskiy sindrom i ego komponenty kak vozmozhnye modificiruemye faktory riska raka (literaturnyy obzor). Sibirskiy onkologicheskiy zhurnal. 2012;2:68-72.
5. Bjorge T., Lukanova A., Jonsson H. Metabolic Syndrome and Breast Cancer in the Me-Can (Metabolic Syndrome and Cancer) Project. Cancer Epidemiol. Biomarkers Prev. 2010;19(7):1737-1745. doihttps://doi.org/10.1158/1055-9965.EPI-10-0230.
6. Johansen D., Stocks T., Jonsson H., Lindkvist B. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2307-2317. doihttps://doi.org/10.1158/1055-9965.EPI-10-0234.
7. Demark-Wahnefried W., Platz E.A. Ligibel J.A., et al. The Role of Obesity in Cancer Survival and Recurrence. Cancer epidemiology, biomarkers Prev. 2012;21:1244- 1259. doi:https://doi.org/10.1158/1055-9965.EPI-12-0485.
8. Marie Ng., Fleming T., Robinson B. S. M. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2014;384(9945):766-781.
9. Prado C. M., Lieffers J. R., McCargar L. J. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629-635. doihttps://doi.org/10.1016/S1470- 2045(08)70153-0.
10. Rask-Andersen M., Jacobsson J. A., Moschonis G., Ek A. E. The MAP2K5-linked SNP rs2241423 is associated with BMI and obesity in two cohorts of Swedish and Greek children. BMC medical genetics. 2012;13(1):36. doi:https://doi.org/10.1186/1471-2350-13-36.
11. Dzhonson R., Endryus P. Gen ozhireniya. V mire nauki. 2016;08/09:112-119.
12. De Pergola G., Silvestris F. Obesity as a major risk factor for cancer. J. Obesity. 2013; 2013:291546. doihttps://doi.org/10.1155/2013/291546.
13. Rothwell P. M., Wilson M., Elwin C. E. Long- term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376(9754):1741-1750. doihttps://doi.org/10.1016/S0140- 6736(10)61543-7.
14. Shtygasheva O. V., Ageeva E. S. Predikciya i prevenciya kolorektal'nogo raka, osnovannaya na patogeneticheskih fenomenah. Krymskiy zhurnal eksperimental'noy i klinicheskoy mediciny. 2019;9(1): 71-80.
15. Shtygasheva O. V., Ageeva E. S., Guzar' Ya. R. Anamnesticheskie prediktory kolorektal'nogo raka. Eksperimental'naya i klinicheskaya gastroenterologiya. 2019;162(2):50-54. doihttps://doi.org/10.31146/1682-8658- ecg-162-2-50-54.
